Galera /
Obsidian
Obsidian to go public through merger with Galera
Source for the buyer and target: Galera Therapeutics, Inc.
For the buyer and target.
“A: We’re excited to announce that Obsidian is taking a major next step in its development, with plans to list on Nasdaq, or “go public,” through a merger transaction with Galera.”
Published 14 Apr 2026
Open the sourceWhat happened
Obsidian told its employees on April 14, 2026 that it plans to list on Nasdaq by merging with Galera. The combined company would operate under the Obsidian Therapeutics name, with Madan Jagasia continuing as CEO and Obsidian's current board leading the combined business. [01]
The merger comes with private financing commitments of about $350M. Obsidian says this would support work on its engineered TIL cell therapy OBX-115 in melanoma and NSCLC. The deal terms weren't disclosed as a price. Obsidian holders are expected to own about 53.2% of the combined company, private placement investors about 45.0% and pre-closing Galera holders about 1.8%. Closing is targeted by the third quarter of 2026. [01]
The source
Everything on this page comes from the source below, quoted word for word.
Obsidian to go public through merger with Galera
This document is the source for the companies, stage, figure and people on this page.
Open the sourceTimeline
Every date the source states, in order, each with the words it comes from. Anything marked ahead is a target the source gives, not something that has happened.
Also stated
“Obsidian to go public through merger with Galera Obsidian told its employees on April 14, 2026 that it plans to list on Nasdaq by merging with Galera”
Open the source
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Get ProAlready a member? Sign in
Pro is open to everyone.
By email · Weekly